Inclusion Criteria:

          -  Phase 1a patients must have locally advanced or metastatic solid tumors,

          -  Phase 1b patients must have locally advanced or metastatic and/or non-resectable head
             and neck squamous cell carcinoma, cholangiocarcinoma, stomach cancer, melanoma,
             pancreatic cancer, NSCLC (as high expression of αVβ3, αVβ5, or αVβ6 have been reported
             for these tumors)

               -  Measurable disease: For Phase 1a patients can have non-measurable or measurable
                  disease. For all other parts: measurable disease defined by RECIST v1.1 is
                  required

               -  For Phase 1a Part 3 and Phase 1b patients (combination treatment) must be
                  refractory or relapsed to anti-PD-1, anti-PD-L1 or anti-CTLA4 checkpoint
                  inhibitors for all tumor types, For Part 1 and Part 2 of Phase 1a (BJ-001 single
                  agent treatment) both checkpoint inhibitor naïve or refractory/relapsed patients
                  will be considered.

          -  Patient who have diagnosis for which treatment with PD-1/PD-L1 inhibitors to be
             enrolled. Patients previously treated with PD-1/PD-L1 inhibitors and who have
             progressed are eligible. to be enrolled.

               -  Adequate hematologic function,

               -  Adequate hepatic function, defined by all of the following:

               -  Adequate renal function defined by estimated creatinine clearance ≥ 45 mL/min
                  (Cockcroft and Gault formula

               -  ECOG Performance Status (PS) of 0-2.

               -  No history of any hematopoietic malignancy.

               -  No active or history of clinically significant autoimmune disease (as defined by
                  previously requiring immunosuppressive therapy).

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Receipt of any investigational product or any approved anticancer drug(s) or
             biological product(s) within 4 weeks prior to the first dose of study drug.
             Exceptions: Hormone replacement therapy, testosterone, or oral contraceptives (LHRH
             antagonists are allowed).

          -  Patients previously treated with an anti PD-1/PD-L1 targeting agent who have had any
             prior history of immune-mediated pneumonitis, any immune-mediated toxicity of ≥ Grade
             3,

          -  Patients with a history of severe allergic or anaphylactic reactions to human mAb
             therapy or known hypersensitivity.

          -  Patients with a history of pneumonitis, myocarditis, history of Stevens-Johnson
             syndrome or toxic epidermal necrolysis.

          -  Patients who have undergone a bone marrow transplantation, solid organ
             transplantation, or stem cell transplant.

          -  Patients with unresolved AEs > Grade 1 from prior anticancer therapy.

          -  Patients who have received prior interferon or IL-2 therapy less than 4 weeks prior to
             enrollment.

          -  Uncontrolled primary central nervous system (CNS) tumors or CNS metastases; based on
             screening.

          -  Patients with active autoimmune disease or a documented medical history of autoimmune
             disease managed by replacement therapy.